CGEM
Cullinan Therapeutics, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$22.09
−0.32%Aug 13, 2026, 15:21 UTC
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced positive Phase 3 trial data for zipalertinib as a first-line treatment for certain lung cancer patients.
Source:Aug 6, 2026, 11:00 UTC
Cullinan Therapeutics announced that it will present multi-dose regimen data for CLN-978 in rheumatoid arthritis in Q3 2026 and in systemic lupus erythematosus in Q4 2026, and will begin Phase 2 expansion studies in early 2027.
Source:Aug 6, 2026, 00:00 UTC
Cullinan Therapeutics reported a net loss of $53.7 million for Q2 2026, with cash and investments of $356.0 million as of June 30, 2026.
Jul 28, 2026, 11:00 UTC
Cullinan Therapeutics received positive feedback from the FDA after an End-of-Phase 1 meeting for CLN-049, advancing the program to a potentially registrational Phase 2 study in acute myeloid leukemia.
Source:Jun 6, 2026, 09:15 UTC
Cullinan Therapeutics presented initial clinical data for CLN-978, a CD19xCD3 T cell engager, at the EULAR 2026 Congress.
Source: